GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

ebdarokimab   Click here for help

GtoPdb Ligand ID: 13875

Synonyms: AK-101 | AK101
Approved drug Immunopharmacology Ligand
ebdarokimab is an approved drug
Compound class: Antibody
Comment: Ebdarokimab (AK101) is a humanized IgG1-κ, dual IL-12/IL-23 targeting monoclonal antibody. It binds to the common p40 subunit (IL12B) of these cytokines and disrupts pro-inflammatory signalling via their receptors on T cells and natural killer (NK) cells.
No information available.
Summary of Clinical Use Click here for help
Ebdarokimab was first approved in China in March 2025, to treat moderate to severe plaque psoriasis by subcutaneous injection.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05120297 A Phase 3 Study of Efficacy and Safety of AK101 in Subjects With Psoriasis Phase 3 Interventional Akeso
NCT05509361 Open Label Study to Evaluate the Safety and Efficacy of AK101 Injection Subcutaneously in Subjects With Psoriasis Phase 3 Interventional Akeso